Danaher Corporation

FluoGuide A/S announced a collaboration with Leica Microsystems, a Danaher company and world leading medical technology company, to advance precision surgery for brain tumors. The agreement is a milestone in brain tumor surgery development, aiming to optimize the use of imaging systems and FluoGuide's lead product FG001 to enable better treatment for patients with high-grade glioma cancer. The focus of the current agreement is to support the clinical phase and to gather a body of evidence on Leica's technology platform. The agreement has no initial payment, is non-exclusive, and its terms are not disclosed; it will not have an impact on FluoGuide's financial results in 2026. FG001 has received both Fast Track and Orphan Drug Designations from the FDA, supporting its development in high-grade glioma in the US, and FluoGuide is listed on Nasdaq First North Sweden under the ticker FLUO.

Leica Biosystems, a Danaher company, has completed its acquisition of privately held StatLab Medical Products, a leading provider of pre-analytical consumables and equipment, from Linden Capital Partners and Audax Private Equity. The transaction closed on September 28, 2026. The company said the deal unites StatLab's trusted portfolio and deep customer relationships with Leica Biosystems' global leadership in digital and computational pathology and AI-enabled diagnostics, expanding its end-to-end anatomic pathology ecosystem from specimen collection and preparation through advanced staining, digital imaging and AI-enabled diagnosis. Gustavo Perez-Fernandez, Group Executive of Danaher's Diagnostics Business and President of Leica Biosystems, said the combined businesses are better positioned to help laboratories achieve the consistency, standardization and quality needed to advance precision oncology at scale. Leica Biosystems said the expanded offering is designed to help pathology laboratories optimize histology workflows and reduce variation amid rising case volumes, increasing complexity and ongoing staffing pressures, and that both businesses remain focused on supporting customers with the same commitment to quality, service and partnership.

Danaher Corporation's Biotechnology segment reported second-quarter 2026 sales of $1.92 billion, up 4% year over year, with core revenues increasing 2.5%. The growth was driven by stronger demand in China, higher consumables and equipment sales in bioprocessing, and improved discovery and medical business. However, difficult prior-year comparisons in Western Europe and North America and shipment timing shifts by large customers remain concerns. Danaher expects the segment's core revenues to grow in the mid-single digits in 2026. Shares of Danaher have gained 24.4% in the past month, and the company carries a Zacks Rank #3 (Hold).

Masimo, a Danaher company, announced FDA 510(k) clearance for its Root with LiDCO hemodynamic monitoring solution, including the Masimo LiDCO sensor, enabling continuous monitoring of oxygen delivery. The system combines continuous noninvasive hemoglobin, Masimo SET oxygen saturation, and cardiac output to provide a beat-to-beat view of oxygen being delivered to tissue. Dr. Basil Matta, Chief Medical Officer at Masimo, said the technology gives clinicians a continuous view of oxygen delivery and helps them better understand changes in a patient's oxygen supply as they occur. Clinical studies cited by the company showed preoperative optimization of oxygen delivery reduced mortality from 17% to 3% in one trial, and another trial demonstrated a 75% reduction in 28-day mortality when targeting oxygen delivery greater than 600 mL/min/m².

Merck and Moderna announced positive topline Phase 3 results for their individualized cancer vaccine intismeran autogene in resected melanoma, beating Keytruda alone on recurrence-free survival, though no specific efficacy numbers have been released yet. The news lifted several biotech names, with BioNTech surging 21.6% on read-across excitement and Illumina rising 15.6% to $223.22 because its NovaSeq X sequencers are required for every individualized neoantigen dose manufactured. Pacific Biosciences gained 5.8% to $1.28, Repligen traded at $181.62 after reporting second-quarter revenue of $204 million with 13% organic growth, and Danaher saw mid-teens bioprocessing order growth in the second quarter. Leerink Partners analyst Daina Graybosch called the market reaction overly optimistic but still raised her 2032 intismeran forecast to $1.4 billion, while Morningstar projects $16.8 billion by 2035.

Danaher Corporation's second-quarter bioprocessing unit miss sent ripples across the life sciences sector, pressuring Bio-Rad Laboratories shares in early New York trading. Danaher reported Q2 2026 revenue of $6.3 billion, up 5.5% year-over-year, with adjusted diluted EPS rising 8% to $1.94 and free cash flow of $1.3 billion, and raised its full-year adjusted EPS guidance to $8.45–$8.60. Bio-Rad posted Q2 net sales of $651 million, essentially flat, with its Life Science segment down 4.1% to $252 million, and announced a restructuring plan on July 31, 2026 involving global headcount reductions and facility closures expected to generate $80 million to $90 million in pre-tax charges. RBC Capital subsequently raised its price target on Bio-Rad to $370 from $320, maintaining an Outperform rating, while Danaher named Julie Sawyer Montgomery as CEO. Hedge fund data showed institutional investors trimmed positions in both stocks during Q1 2026, with Bio-Rad held by 35 hedge funds and Danaher by 110.

The crisis of antimicrobial resistance, or superbugs, is driving investment into the AMR Diagnostics sector, which serves as the diagnostic and containment infrastructure for drug-resistant infections. By 2050, superbugs could claim more lives than cancer if adequate systems are not in place. Danaher Corporation, through its subsidiary Cepheid, leads in molecular diagnostic radar systems with the GeneXpert instrument, generating recurring revenue from test cartridges. Meanwhile, Becton, Dickinson and Company dominates the automated microbiology lab market with a consumables sales model that carries very high switching costs. Investment in this sector is thus seen as a defensive theme with predictable cash flows and strong demand from public health systems worldwide.

Danaher shares may be undervalued by about 16% relative to a fair value estimate of $228.61, according to a Simply Wall St analysis, even after the stock fell 16.9% year to date. The company recently issued third quarter 2026 revenue guidance of 2% to 3% growth and detailed share repurchases alongside its latest quarterly earnings. The fair value estimate assumes mid-single-digit revenue expansion, faster earnings growth, and a richer margin mix driven by life sciences and diagnostics, including AI-assisted diagnostic solutions and support for in vivo CRISPR therapies. However, the narrative also depends on bioprocessing recovery and China, where policy shifts and lumpy consumables demand could unsettle those assumptions.

Danaher shares fell 12.1% this week despite second-quarter earnings beating estimates and management raising full-year EPS guidance to $8.45-$8.60 from $8.35-$8.55. The decline was driven by a reduction in full-year core sales growth expectations for the high-margin biotechnology segment, where consumables sales missed expectations due to a few large chromatography resin shipments moving out of the year. Analysts questioned why the shipments would not simply shift to later quarters, and CEO Rainer Blair confirmed the timing change. The sell-off appears to be an overreaction to an otherwise positive report, presenting a potential buying opportunity for long-term investors.

Apple failed to overturn a $634 million jury verdict in a patent dispute with medical technology company Masimo. A federal judge in California rejected Apple's request to set aside the award, which centered on blood oxygen measurement technology in certain Apple Watch models. The court also found that Apple misappropriated two of 14 Masimo trade secrets but declined to issue an injunction and ruled that Masimo could not seek monetary damages on that part of the case. Masimo, now part of Danaher, had sought as much as $3.1 billion tied to the trade-secret claims and has filed an appeal over that portion of the ruling. Apple has argued that its engineers developed the health-monitoring features independently.

Danaher Corporation reported second-quarter 2026 revenue of $6.3 billion, with core revenue up 3% year-over-year, and raised its full-year adjusted diluted EPS guidance to a range of $8.45 to $8.60. Non-respiratory core growth accelerated to 4.5%, a 150-basis-point improvement from the first quarter, driven by recovery in life sciences and diagnostics end markets. Adjusted diluted EPS came in at $1.94, an 8% increase, while free cash flow reached $1.3 billion for the quarter. The company closed its acquisition of Masimo in early June, which delivered high single-digit revenue growth in the first half, and announced the pending acquisition of StatLab, a pathology consumables manufacturer with approximately $250 million in 2025 revenue. Bioprocessing orders grew mid-teens in both consumables and equipment, though approximately $100 million in chromatography resin revenue shifted from 2026 into 2027 due to customer site readiness and production schedule changes. Full-year core revenue guidance was maintained at 3% to 4%, with third-quarter revenue growth expected at 2% to 3%, including a 250-basis-point headwind from respiratory testing.

Danaher reported better-than-expected second-quarter results with sales of $6.3 billion, adjusted EPS of $1.94, and $1.3 billion in free cash flow. Core revenue rose 3% year over year, while the Life Sciences segment posted 5.5% core growth, its strongest quarter in several years. The company raised full-year 2026 adjusted EPS guidance to a range of $8.45 to $8.60, while keeping core revenue growth guidance at 3% to 4%. Management said bioprocessing shipment delays hurt the quarter, but underlying demand remained strong and life sciences strength is expected to offset some of that pressure.

The global high-throughput screening market is projected to grow from USD 27.66 billion in 2026 to USD 45.90 billion by 2031, at a compound annual growth rate of 10.7 percent, according to a new report from MarketsandMarkets. Growth is driven by rising pharmaceutical and biotechnology R&D investments, increasing adoption of automated drug discovery platforms, and technological advances in areas such as cell-based screening and artificial intelligence-enabled analytics. The products segment accounted for the largest share of the market in 2025, with reagents, kits and consumables being the largest product type due to their recurring use across screening workflows. Asia Pacific is expected to register the highest growth rate during the forecast period, supported by expanding research activities and growing contract research organization presence in countries including China, India, Japan, and South Korea. Key players in the market include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Danaher Corporation, and Revvity, with the top participants collectively holding approximately 38 percent of the global market.

Danaher Corporation is scheduled to release second-quarter 2026 results on July 21 before market open, with the Zacks Consensus Estimate for revenues pegged at $6.09 billion and earnings at $1.84 per share. The earnings estimate has risen a penny in the past seven days and implies a 2.2% increase from the year-ago quarter, while the revenue estimate indicates a 2.6% rise. The company's bottom line surpassed the consensus in each of the preceding four quarters, delivering an average beat of 6.7%. Zacks' model predicts another beat this time, as Danaher carries an Earnings ESP of +0.62% and a Zacks Rank of 2. Key drivers include strength in the bioprocessing business within the Biotechnology segment, where the consensus sales estimate is $1.95 billion, and the June 2026 acquisition of Masimo Corp. for $9.9 billion, which is expected to have enhanced the diagnostics portfolio. However, escalating costs and higher interest expenses may have weighed on profitability.

The global life science tools market is projected to grow from USD 175.96 billion in 2025 to USD 503.69 billion by 2035, at a compound annual growth rate of 11.09%, according to a new report by SNS Insider. North America led the market in 2025, with the U.S. segment valued at USD 68.50 billion and forecast to reach USD 189.48 billion by 2035, while the Asia-Pacific region is expected to record the fastest growth at a CAGR of more than 12%. Next-generation sequencing held the largest technology share at over 30% in 2025 and is also the fastest-growing technology segment, driven by applications in single-cell sequencing, liquid biopsy, and rare diseases. Instruments accounted for more than 52% of the market by type, and biopharmaceutical companies represented the largest end-user segment with an estimated 44% share. Key players include Agilent Technologies, Illumina, Thermo Fisher Scientific, and Danaher, with recent developments such as Agilent's expansion of its genomics portfolio in 2025 and Illumina's enhanced sequencing platforms in 2024.

The global laboratory centrifuges market is projected to grow from USD 1.58 billion in 2025 to USD 1.86 billion by 2030, at a compound annual growth rate of 2.8%. Equipment held the largest product segment share in 2025, driven by technology upgrades and replacement cycles. Benchtop centrifuges led the platform segment due to their affordability and compact footprint, while hospitals remained the largest end-user segment because of high diagnostic testing volumes. Asia Pacific is expected to register the highest regional growth rate, fueled by healthcare infrastructure investments in China and India. Key players include Thermo Fisher Scientific, Danaher, and Eppendorf.

The South Korea automated liquid handling system market is projected to grow from $23.5 million in 2025 to $51.0 million by 2036, at a compound annual growth rate of 7.47%. The automated liquid handling system segment is expected to dominate by type, while liquid handling workstations lead by product. Drug discovery is the leading application, and pharmaceutical and biotechnology companies are the primary end users. Key players include Agilent Technologies, Revvity, Thermo Fisher Scientific, Danaher, and Tecan Group.

Beckman Coulter Diagnostics, part of Danaher, has received CE Mark under IVDR for its Access p-Tau217 blood assay. The regulatory milestone arrives as Danaher's stock trades at $190.77, down 17.2% year to date, with a one-year total shareholder return of negative 4.37%. Analyst targets and one intrinsic value estimate place fair value roughly 26% higher, while a popular narrative pegs fair value at $242.35, suggesting the stock is undervalued. A discounted cash flow model estimates fair value at $259.47, though pressure on biotech and academic spending, along with China policy changes affecting diagnostics revenue, could challenge the bullish case.

Danaher Corporation's Biotechnology segment core revenues increased 7% year over year in the first quarter of 2026, driven by strength in the bioprocessing business and higher sales in Western Europe and China. Bioprocessing orders for equipment rose more than 30%, and the company expects core revenues from bioprocessing to grow in high single digits for the full year. Despite headwinds from weak demand for medical filtration and research consumables, Danaher anticipates mid-single-digit core revenue growth for the Biotechnology segment in the second quarter. The company's shares have gained 3% in the past month, and it carries a Zacks Rank of 2, or Buy.

The global exosome diagnostics market is projected to reach USD 815.0 million by 2031, growing at a compound annual growth rate of 11.8% from USD 466.2 million in 2026. Growth is driven by rising demand for minimally invasive diagnostics, advancements in biomarker discovery, and increasing adoption of liquid biopsy technologies, particularly in oncology. North America leads the market due to advanced healthcare infrastructure, while Asia-Pacific is expected to see rapid expansion fueled by investments in countries like China and India. Key players include Danaher Corporation, Thermo Fisher Scientific, and Exosome Diagnostics Inc., with competition centered on product innovation and strategic partnerships. Challenges include standardization of exosome isolation and regulatory uncertainty.

Danaher has completed its $9.9 billion acquisition of Masimo Corporation, a specialist in pulse oximetry and patient monitoring solutions. Masimo will now operate as a standalone company within Danaher's Diagnostics segment, retaining its brand identity as a wholly owned subsidiary, and its common stock has been delisted from the NASDAQ. Danaher views the deal as a strategic move to enhance its diagnostics portfolio in acute care settings through Masimo's sensor and AI-monitoring technologies, expecting it to accelerate Masimo's global reach. The company's current 2026 guidance remains unchanged for the second quarter, as Masimo is not expected to contribute materially until later in the year, with updated full-year 2026 financial guidance to be provided during the second-quarter earnings release.